Table 1. Baseline characteristics of the groups.
Group HF-S/V, patients undergoing treatment with sacubitril/valsartan; Group HF-CT, patients receiving conventional therapy
*T-test
**Chi-square
SD, standard deviation; HF, heart failure; HBP, high blood pressure; LVEF, left ventricle ejection fraction; NYHA, New York Heart Association
| Parameter | Group HF-CT | Group HF-S/V | P-value |
| Age, Mean, SD (N) | 63.467 ± 11.509 (197) | 66.327 ± 11.246 (55) | 0.103* |
| Male, N, % | 100 (50.76) | 34 (61.81) | 0.099** |
| Rural area, N (%) | 57 (28.93) | 25 (45.45) | 0.021** |
| Weight, N (%) | 197 (100) | 55 (100) | 0.338** |
| Normal weight, N (%) | 6 (10.90) | 36 (18.27) | <0.001** |
| Overweight, N (%) | 62 (31.47) | 20 (36.36) | <0.001** |
| Grade I obesity, N (%) | 56 (28.42) | 21 (38.18) | 0.0001 |
| Grade II obesity, N (%) | 30 (15.22) | 8 (14.54) | 0.0004 |
| Grade III obesity, N (%) | 11 (5.58) | - | - |
| Underweight, N (%) | 2 (1.01) | - | - |
| HF, N (%) | 197 (100) | 55 (100) | <0.0001** |
| Class I NYHA, N (%) | 91 (46.19) | 3 (5.45) | <0.0001** |
| Class II NYHA, N (%) | 101 (51.26) | 44 (80.00) | <0.0001** |
| Class III NYHA, N (%) | 5 (2.53) | 8 (14.54) | 0.405** |
| HBP, N (%) | 179 (90.86) | 40 (72.72) | <0.001** |
| Stage I, N (%) | 34 (17.25) | 4 (7.27) | <0.0001** |
| Stage II, N (%) | 114 (57.86) | 35 (63.63) | <0.0001** |
| Stage III, N (%) | 31 (15.73) | 1 (1.81) | <0.0001** |
| Diabetes mellitus, N (%) | 113 (57.36) | 34 (61.81) | 0.553** |
| Dyslipidemia, N (%) | 172 (87.31) | 41 (74.54) | 0.021** |
| Peripheral venous disease, N (%) | 45 (22.84) | 9 (16.36) | 0.300** |
| Dilated cardiomyopathy, N (%) | 19 (9.64) | 46 (83.63) | <0.001** |
| Chronic kidney disease, N (%) | 32 (16.24) | 19 (34.54) | 0.008** |
| Lung disease, N (%) | 22 (11.16) | 13 (23.63) | 0.018** |
| LVEF, N (%) | 197 (100) | 55 (100) | <0.001** |
| LVEF < 40%, N (%) | 7 (3.55) | 38 (69.09) | <0.0001** |
| LVEF ≤ 40%-50%, N (%) | 21 (10.66) | 14 (25.45) | 0.236 |
| LVEF ≥ 50%, N (%) | 169 (85.78) | 3 (5.45) | <0.0001** |